THERATECHNOLOGIES INC (THTX) Stock Price, Quote, News and Overview
NASDAQ:THTX - Nasdaq - CA88338H7040 - Common Stock - Currency: USD
THTX Quote, Performance and Key Statistics
NASDAQ:THTX (5/30/2025, 3:32:59 PM)
2.64
+0.04 (+1.54%)
The current stock price of THTX is 2.64 USD. In the past month the price decreased by -8.45%. In the past year, price increased by 108%.
THTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.14 | 329.04B | ||
| AMGN | AMGEN INC | 13.87 | 154.84B | ||
| GILD | GILEAD SCIENCES INC | 14.25 | 137.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.95B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.09 | 53.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.83B | ||
| ARGX | ARGENX SE - ADR | 98.28 | 35.23B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.3 | 26.62B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.01B | ||
| NTRA | NATERA INC | N/A | 21.33B | ||
| BIIB | BIOGEN INC | 8.3 | 19.24B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.68 | 14.33B |
Related stock screener links
About THTX
Company Profile
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 94 full-time employees. The firm is focused on the development and commercialization of therapies addressing unmet medical needs. The company markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The firm's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
Company Info
THERATECHNOLOGIES INC
2015 Peel Street, 11th Floor
MONTREAL QUEBEC H3A 1T8 CA
CEO: Paul Levesque
Employees: 103
Phone: 15143367800
THERATECHNOLOGIES INC / THTX FAQ
What is the stock price of THERATECHNOLOGIES INC today?
The current stock price of THTX is 2.64 USD. The price increased by 1.54% in the last trading session.
What is the ticker symbol for THERATECHNOLOGIES INC stock?
The exchange symbol of THERATECHNOLOGIES INC is THTX and it is listed on the Nasdaq exchange.
On which exchange is THTX stock listed?
THTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for THERATECHNOLOGIES INC stock?
10 analysts have analysed THTX and the average price target is 4.05 USD. This implies a price increase of 53.43% is expected in the next year compared to the current price of 2.64. Check the THERATECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is THERATECHNOLOGIES INC worth?
THERATECHNOLOGIES INC (THTX) has a market capitalization of 121.39M USD. This makes THTX a Micro Cap stock.
How many employees does THERATECHNOLOGIES INC have?
THERATECHNOLOGIES INC (THTX) currently has 103 employees.
What are the support and resistance levels for THERATECHNOLOGIES INC (THTX) stock?
THERATECHNOLOGIES INC (THTX) has a support level at 2.59 and a resistance level at 2.78. Check the full technical report for a detailed analysis of THTX support and resistance levels.
Is THERATECHNOLOGIES INC (THTX) expected to grow?
The Revenue of THERATECHNOLOGIES INC (THTX) is expected to decline by -1.97% in the next year. Check the estimates tab for more information on the THTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy THERATECHNOLOGIES INC (THTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of THTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of THTX, evaluating the profitability, health, valuation and growth aspects
- THERATECHNOLOGIES INC (THTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- THERATECHNOLOGIES INC (THTX) Sales and EPS estimates to see what analysts future expectations are.
- THERATECHNOLOGIES INC (THTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- THERATECHNOLOGIES INC (THTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- THERATECHNOLOGIES INC (THTX) Stock Chart to make your own analysis
- THERATECHNOLOGIES INC (THTX) Latest news and press-releases to stay up to date.
Does THERATECHNOLOGIES INC (THTX) stock pay dividends?
THTX does not pay a dividend.
When does THERATECHNOLOGIES INC (THTX) report earnings?
THERATECHNOLOGIES INC (THTX) will report earnings on 2025-07-08, before the market open.
What is the Price/Earnings (PE) ratio of THERATECHNOLOGIES INC (THTX)?
THERATECHNOLOGIES INC (THTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
What is the Short Interest ratio of THERATECHNOLOGIES INC (THTX) stock?
The outstanding short interest for THERATECHNOLOGIES INC (THTX) is 1.23% of its float. Check the ownership tab for more information on the THTX short interest.
THTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to THTX. When comparing the yearly performance of all stocks, THTX is one of the better performing stocks in the market, outperforming 97.6% of all stocks.
THTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THTX. There are concerns on the financial health of THTX while its profitability can be described as average.
THTX Financial Highlights
Over the last trailing twelve months THTX reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 86.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
THTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to THTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 147.68% and a revenue growth -1.97% for THTX